IL314179A - Compositions and methods for the treatment of depression - Google Patents
Compositions and methods for the treatment of depressionInfo
- Publication number
- IL314179A IL314179A IL314179A IL31417924A IL314179A IL 314179 A IL314179 A IL 314179A IL 314179 A IL314179 A IL 314179A IL 31417924 A IL31417924 A IL 31417924A IL 314179 A IL314179 A IL 314179A
- Authority
- IL
- Israel
- Prior art keywords
- level
- patient
- dynorphin
- biomarker
- identified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298047P | 2022-01-10 | 2022-01-10 | |
| PCT/IB2023/050170 WO2023131920A1 (en) | 2022-01-10 | 2023-01-09 | Compositions and methods for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL314179A true IL314179A (en) | 2024-09-01 |
Family
ID=84981555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL314179A IL314179A (en) | 2022-01-10 | 2023-01-09 | Compositions and methods for the treatment of depression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250221960A1 (https=) |
| EP (1) | EP4463152A1 (https=) |
| JP (1) | JP2025503646A (https=) |
| KR (1) | KR20240132479A (https=) |
| CN (1) | CN118510507A (https=) |
| AU (1) | AU2023205471A1 (https=) |
| CA (1) | CA3247760A1 (https=) |
| IL (1) | IL314179A (https=) |
| MX (1) | MX2024008618A (https=) |
| WO (1) | WO2023131920A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024336807A1 (en) * | 2023-09-06 | 2026-04-16 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant for use in treating major depressive disorder |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) * | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
-
2023
- 2023-01-09 MX MX2024008618A patent/MX2024008618A/es unknown
- 2023-01-09 IL IL314179A patent/IL314179A/en unknown
- 2023-01-09 CN CN202380016647.0A patent/CN118510507A/zh active Pending
- 2023-01-09 US US18/727,772 patent/US20250221960A1/en active Pending
- 2023-01-09 WO PCT/IB2023/050170 patent/WO2023131920A1/en not_active Ceased
- 2023-01-09 AU AU2023205471A patent/AU2023205471A1/en active Pending
- 2023-01-09 JP JP2024541193A patent/JP2025503646A/ja active Pending
- 2023-01-09 CA CA3247760A patent/CA3247760A1/en active Pending
- 2023-01-09 EP EP23700339.7A patent/EP4463152A1/en active Pending
- 2023-01-09 KR KR1020247026164A patent/KR20240132479A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4463152A1 (en) | 2024-11-20 |
| CN118510507A (zh) | 2024-08-16 |
| JP2025503646A (ja) | 2025-02-04 |
| KR20240132479A (ko) | 2024-09-03 |
| WO2023131920A1 (en) | 2023-07-13 |
| CA3247760A1 (en) | 2023-07-13 |
| US20250221960A1 (en) | 2025-07-10 |
| AU2023205471A1 (en) | 2024-08-29 |
| MX2024008618A (es) | 2024-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Ferrostatin-1 obviates seizures and associated cognitive deficits in ferric chloride-induced posttraumatic epilepsy via suppressing ferroptosis | |
| Zykova et al. | Macrophage stimulating agent soluble yeast β‐1, 3/1, 6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study | |
| Chang et al. | Hyaluronan regulates PPARγ and inflammatory responses in IL-1β-stimulated human chondrosarcoma cells, a model for osteoarthritis | |
| Diez-Porras et al. | Guillain-Barré-Strohl syndrome and COVID-19: case report and literature review | |
| BR0314236A (pt) | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos | |
| NO20052242L (no) | Noytraliserende antistoffer mot GDF-8 og deres anvendelse. | |
| JP2014525465A5 (https=) | ||
| KR20130043145A (ko) | 국소 적용을 위한 신규의 상승적 약제학적 조성물 | |
| JP7788730B2 (ja) | コロナウィルス感染症の治療薬 | |
| US12168010B2 (en) | Use of co-enzyme antagonists to slow metabolism | |
| WO2022008971A3 (en) | Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho | |
| Gruber et al. | A double‐blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| BR112022015361A2 (pt) | Composição farmacêutica para prevenir ou tratar doenças pulmonares, composição de alimentos funcionais para a saúde para melhorar ou prevenir doenças pulmonares e método de prevenção ou tratamento de doenças pulmonares em um indivíduo em necessidade do mesmo | |
| Constantin | Evaluation of Cumulative Effects of Chemotherapy and Bevacizumab (Avastin�) in Oncological Patients with Periodontal Disease | |
| IL314179A (en) | Compositions and methods for the treatment of depression | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| Yue et al. | Treatment of refractory progressive vitiligo with oral upadacitinib and narrow‐band ultraviolet‐B: A case series. | |
| Yingsakmongkol et al. | Effect of WF10 (immunokine) on diabetic foot ulcer therapy: a double-blind, randomized, placebo-controlled trial | |
| Chen et al. | Tyrosol promotes skin flap survival by downregulating the p38/NF-κB signaling pathway | |
| BRPI0411010A (pt) | métodos para manter ou aumentar o número de glóbulos brancos do sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer, para manter ou aumentar o número de plaquetas no sangue em um paciente com cáncer submetido a tratamento quimioterapêutico para cáncer e para reduzir a toxicidade gastrintestinal em um paciente com cáncer resultante de um agente quimioterapêutico anti-cáncer, composição farmacêutica, e, kit | |
| WO2023086663A3 (en) | Methods for tauopathy diagnosis and treatment | |
| IL314176A (en) | Compositions and methods for treating depression | |
| Qin et al. | Heme oxygenase‐1 therapy attenuates muscle atrophy following global brachial plexus avulsion in juvenile rats | |
| EP1804789A4 (en) | METHOD FOR TREATING PREECLAMPSY IN HUMANS WITH RESIBUFAGENIN |